This innovative vaccine, known as BNT116 and developed by BioNTech, is designed to combat non-small cell lung cancer ...

Researchers leading the trial have said that BioNTech’s BNT116 vaccine could improve survival rates among people with the ...

(RTTNews) - Kuick Research announced the initiation of the first mRNA lung cancer vaccine trials globally with German biotech firm BioNTech SE's (BNTX) BNT116 as a significant breakthrough in ...

At the United Kingdom's National Institute for Health Research (NIHR) on Tuesday, doctors delivered the 67-year-old's introductory dose of BNT116. The messenger RNA (mRNA) immunotherapy will ...

BioNTech has announced the initiation of global clinical trials for BNT116, an mRNA vaccine for the potential treatment of non-small cell lung cancer (NSCLC). The vaccine is claimed to use the ...

As your White House correspondent, I ask the tough questions and seek the answers that matter. Your support enables me to be in the room, pressing for transparency ...

This innovative project, featuring BioNTech’s BNT116, heralds the dawn of a transformative period in cancer therapy domain, with the potential to fundamentally change our strategies for cancer ...

Researchers leading the trial have said that BioNTech’s BNT116 vaccine could improve survival rates among people with the disease, and hope that it could eventually become the standard of care ...

This innovative project, featuring BioNTech’s BNT116, heralds the dawn of a transformative period in cancer therapy domain, with the potential to fundamentally change our strategies for cancer therapy ...